Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study
Author(s): ,
Vincent Mallet
Affiliations:
Institut Pasteur, Inserm, Unité 1223, Paris, France
Corresponding author. Address: Département d’Hépatologie, AP-HP, Hôpital Cochin; Université Paris Descartes, Paris, France, Inserm UMS20, Institut Pasteur; Paris, France; Tel.: +33 (0) 1 58 41 30 12.
,
Stanislas Pol
Affiliations:
Institut Pasteur, Inserm, Unité 1223, Paris, France
,
Philippe Sogni
Affiliations:
Institut Pasteur, Inserm, Unité 1223, Paris, France
,
Alain Hernvann
Affiliations:
Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Cochin, Biology Service, Paris, France
,
Rui Batista
Affiliations:
Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Cochin, Pharmacy Service, Paris, France
,
Anais Vallet-Pichard
Affiliations:
Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Cochin, Hepatology Service, France
Lucia Parlati
Affiliations:
Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Cochin, Hepatology Service, France
EASL LiverTree™. Mallet V. Dec 1, 2018; 256750
Prof. Vincent Mallet
Prof. Vincent Mallet

Access to this content is an EASL members and LiverTree™ Privileged Users benefit.

Journal Abstract
References
Discussion Forum (0)
Rate & Comment (0)
This article does not have an abstract to display.Keyword(s)
Immune checkpoint inhibitor, Drug-induced liver injury, Observational study
[1]. E. De Martin - Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
[2]. N.P. Chalasani - ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
[3]. A.M. Eggermont - Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
[4]. J.S. Weber - Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma
[5]. A.M.M. Eggermont - Adjuvant pembrolizumab versus placebo in resected stage III melanoma
[6]. L. Gandhi - Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
[7]. A.B. El-Khoueiry - Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings